Sutro Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STRO research report →
Range $48 – $56
Price Chart
About the company
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders.
- CEO
- Jane Chung
- IPO
- 2018
- Employees
- 129
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on STRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $142.77M
- P/E
- -0.68
- PEG
- -0.01
- P/S
- 3.17
- P/B
- -1.08
- EV/EBITDA
- -3.22
- Div Yield
- 0.00%
- Gross Margin
- 94.41%
- Op Margin
- -255.20%
- Net Margin
- -344.22%
- ROE
- 142.71%
- ROIC
- -88.53%
Latest fiscal year · YoY change
- Revenue
- $102.48M+65.2%
- Gross Profit
- $95.16M+73.6%
- Op Income
- $-104,952,000
- Net Income
- $-191,086,000+16.0%
- EPS
- $-22.49+24.0%
- OCF Growth
- +7.5%
- FCF Growth
- +8.1%
- 52W High
- $43.85
- 52W Low
- $7.15
- 50D MA
- $12.22
- 200D MA
- $22.61
- Beta
- 1.55
- RSI (14)
- 34
- Avg Volume
- 304.90K
No earnings-call transcripts are available for STRO yet.
- Free Float
- 62.0%
- Shares Outstanding
- 16.60M
- Float Shares
- 10.29M
of shares held by institutions
101 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 1.25M | 0 |
| Blackrock, Inc. | 1.18M | ▲ 55.54K |
| Affinity Asset Advisors, LLC | 1.15M | ▼ 20.00K |
| Samsara Biocapital, LLC | 1.06M | 0 |
| Perceptive Advisors LLC | 970.85K | ▼ 334.00K |
| Kynam Capital Management, LP | 872.56K | 0 |
| Orbimed Advisors LLC | 743.94K | 0 |
| Vanguard Capital Management LLC | 676.93K | ▼ 17.29K |
| Acadian Asset Management LLC | 557.87K | ▲ 184.03K |
| Velan Capital Investment Management LP | 510.04K | ▼ 2.12K |
| Goldman Sachs Group Inc | 496.79K | ▲ 347.58K |
| T. Rowe Price Investment Management, Inc. | 411.65K | ▲ 411.65K |
Held by 163 ETFs
Biggest fund positions in STRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Gerber Hans-Peter | other | 3,750 |
| Sep 18, 26 | Gerber Hans-Peter | other | 1,345 |
| Sep 18, 26 | Gerber Hans-Peter | other | 3,750 |
| Jun 5, 26 | Wigginton Jon Marc | other | 10,000 |
| Jun 5, 26 | Petree Daniel H | other | 10,000 |
| Jun 5, 26 | PANEK JAMES P | other | 10,000 |
| Jun 5, 26 | Lobacki Joseph M | other | 10,000 |
| Jun 5, 26 | Jagpal Sukhi | other | 10,000 |
| Jun 5, 26 | Hunter Heidi | other | 10,000 |
| Jun 5, 26 | Dybbs Michael | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STRO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on STRO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com · Nov 12
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
zacks.com · Nov 4
Sutro Biopharma to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 4
Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround
zacks.com · Nov 3
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
globenewswire.com · Oct 21
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
globenewswire.com · Sep 29
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis
defenseworld.net · Aug 29
Why is Sutro Biopharma Stock Falling On Wednesday?
benzinga.com · Aug 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
